SCHEMBL6786381

SCHEMBL6786381

C/C(=C/C(=O)Nc1cc(NS(C)(=O)=O)ccc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.69
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
DEGS1 O15121 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GPR27 Q9NS67 1/20 0.40
LTB4R Q15722 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AKR1C3 P42330 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
PTGS2 P35354 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785193 0.92 TERT (0.69) TERTDEGS1ALDH1A1MEN1KMT2A
SCHEMBL6787659 0.90 TERT (0.56) TERTALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL6790238 0.90 TERT (0.67) TERTALDH1A1MEN1KMT2AKDM4E
SCHEMBL6787585 0.86 TERT (0.73) TERTGRIK1GRIK2DEGS1ALDH1A1
SCHEMBL6783732 0.85 TERT (0.85) TERTGRIK1GRIK2DEGS1KDM4E
SCHEMBL6791675 0.84 TERT (0.71) TERTGRIK1GRIK2DEGS1ALDH1A1
SCHEMBL6787225 0.83 TERT (0.68) TERTGRIK1GRIK2DEGS1ALDH1A1
SCHEMBL6785060 0.83 TERT (0.68) TERTGRIK1GRIK2DEGS1MEN1
SCHEMBL6785228 0.83 TERT (0.78) TERTGRIK1GRIK2KDM4ELTB4R
SCHEMBL6785319 0.82 TERT (0.71) TERTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885GRIK1 4242/4885GRIK2 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.